← All trials
NCT04660929
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 2, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Feb 28, 2023
- First posted
- Dec 9, 2020
- Last posted
- Nov 17, 2021
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Carisma TherapeuticsLead sponsor
- Carisma TherapeuticsStudy director
Drugs studied
Indications studied
- Carcinoma, Ovarian Epithelial
- Adenocarcinoma
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Head and Neck Neoplasms
- Carcinoma, Hepatocellular
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Stomach Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
- Carcinoma, Small Cell
- Genes, erbB-2
- Carcinoma, Ductal
- Small Cell Lung Carcinoma
- Inflammatory Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.